Nextgen Biomed Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Nextgen Biomed.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.0%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

We Think Nextgen Biomed (TLV:NXGN) Can Afford To Drive Business Growth

Aug 22
We Think Nextgen Biomed (TLV:NXGN) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Nextgen Biomed's (TLV:NXGN) Cash Burn Situation

May 02
Here's Why We're Not Too Worried About Nextgen Biomed's (TLV:NXGN) Cash Burn Situation

We're Hopeful That Nextgen Biomed (TLV:NXGN) Will Use Its Cash Wisely

Jan 13
We're Hopeful That Nextgen Biomed (TLV:NXGN) Will Use Its Cash Wisely

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nextgen Biomed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TASE:NXGN - Analysts future estimates and past financials data (ILS Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-14-3-3N/A
3/31/2024N/A-14-4-4N/A
12/31/2023N/A-14-4-4N/A
9/30/2023N/A-12-4-4N/A
6/30/2023N/A-9-4-4N/A
3/31/2023N/A-9-3-3N/A
12/31/2022N/A-9-3-3N/A
9/30/2022N/A-6-3-3N/A
6/30/2022N/A-3-3-3N/A
3/31/2022N/A-3-3-3N/A
12/31/2021N/A-3-3-3N/A
9/30/2021N/A-2-3-2N/A
6/30/2021N/A-2-3-2N/A
3/31/2021N/A-2-2-2N/A
12/31/2020N/A-1-2-2N/A
9/30/2020N/A-1-2-2N/A
6/30/2020N/A-2-1-1N/A
3/31/2020N/A-1-1-1N/A
12/31/2019N/A-1-1-1N/A
9/30/2019N/A-1-1-1N/A
6/30/2019N/A-1-1-1N/A
3/31/2019N/A-1-1-1N/A
12/31/2018N/A-1-1-1N/A
9/30/2018N/A-1-1-1N/A
6/30/2018N/A-1-1-1N/A
3/31/2018N/A-1N/A-1N/A
12/31/2017N/A-1N/A-2N/A
9/30/2017N/A-2N/A-2N/A
6/30/2017N/A-2N/A-2N/A
3/31/2017N/A-2N/A-2N/A
12/31/2016N/A-2N/A-2N/A
9/30/2016N/A-1N/A-2N/A
6/30/2016N/A-2N/A-2N/A
3/31/2016N/A-3N/A-3N/A
12/31/2015N/A-4N/A-4N/A
9/30/2015N/A-6N/A-4N/A
6/30/2015N/A-6N/A-4N/A
3/31/2015N/A-6N/A-4N/A
12/31/2014N/A-5N/A-3N/A
9/30/2014N/A-4N/A-3N/A
6/30/2014N/A-7N/A-2N/A
3/31/2014N/A-9N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NXGN's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if NXGN's earnings are forecast to grow faster than the IL market

High Growth Earnings: Insufficient data to determine if NXGN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NXGN's revenue is forecast to grow faster than the IL market.

High Growth Revenue: Insufficient data to determine if NXGN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NXGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies